Get the Stockscreener App
3.63
0.68%
-0.065
X 4 Pharmaceuticals Inc stock is traded at $3.63, with a volume of 7,129.
It is down -0.68% in the last 24 hours and down -8.25% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.695
Open:
$3.66
24h Volume:
7,129
Relative Volume:
0.01
Market Cap:
$342.85M
Revenue:
$9.01M
Net Income/Loss:
$-99.72M
P/E Ratio:
-0.7999
EPS:
-4.5381
Net Cash Flow:
$-92.85M
1W Performance:
-4.18%
1M Performance:
-8.25%
6M Performance:
-0.81%
1Y Performance:
+144.67%
1-Day Range:
$3.635
$3.685
1-Week Range:
$3.56
$3.89
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.635 | 348.51M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
470.64 | 119.94B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
643.42 | 68.27B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
870.07 | 53.28B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.09 | 38.91B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.11 | 35.65B | 4.29B | 577.22M | 641.34M | 4.2086 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com South Africa
Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy - Buffalo News
Frontier tech research, news & data - MLQ.ai
X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 4 Eton Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Canada
Catalyst Pharma (CPRX) director cashes out stock and options in $31.50 Angelini buyout - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) HR chief equity cashed out at $31.50 - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) director equity converted to cash at $31.50 - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO equity awards canceled for cash in Angelini merger - Stock Titan
Form 4 Eton Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Nigeria
Form 4 Adial Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Canada
Form 4 Phathom Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Nigeria
Form 4 Shuttle Pharmaceuticals Inc For: 15 July By Investing.com - Investing.com Canada
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? - TradingView
Form 4 Armata Pharmaceuticals Inc For: 14 July By Investing.com - Investing.com Nigeria
Form 4 Eton Pharmaceuticals Inc For: 14 July By Investing.com - Investing.com Canada
Form 4 Shuttle Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Canada
Form 4 Adial Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Canada
XFOR Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentAdjusted Earnings Analysis - dars.gov.et
Layoff Tracker: EMD Serono may trim R&D workforce by up to 70 - BioSpace
X4 Pharmaceuticals (XFOR) Q1 2026 earnings summary - Quartr
X4 Pharmaceuticals (XFOR) Proxy filing Summary - Quartr
X4 Pharmaceuticals (XFOR) Q4 2025 earnings summary - Quartr
X4 Pharmaceuticals (XFOR) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
X4 Pharmaceuticals (XFOR) Corporate presentation Summary - Quartr
X4 Pharmaceuticals (XFOR) Registration filing Summary - Quartr
X4 Pharmaceuticals (XFOR) Rallies 11.36% as Positive Sentiment Drives Price Above Key SupportProfit Surge Picks - Bölüm Sonu Canavarı
Form 4 Rigel Pharmaceuticals Inc For: 10 July By Investing.com - Investing.com Nigeria
Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Form 4 Shuttle Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
Form 4 Ironwood Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Form 4 Recursion Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals stock focuses on rare disease pipeline after Nasdaq listing - ad-hoc-news.de
Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com Nigeria
Form 4 Oric Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com South Africa
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead - TradingView
X4 Pharmaceuticals (XFOR) Stifel 2024 Healthcare Conference Summary - Quartr
Form 4 Eton Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Form 4 Xeris Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Form 4 Crinetics Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Form 4 Regeneron Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Form 4 Vertex Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Canada
Form 4 ANI Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Nigeria
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KIRSKE DAVID | Chief Financial Officer |
May 12 '26 |
Sale |
4.29 |
16,961 |
72,820 |
176,293 |
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):